NASDAQ:EXAI - Nasdaq - US30223G1022 - ADR - Currency: USD
4.84
+0.15 (+3.2%)
The current stock price of EXAI is 4.84 USD. In the past month the price decreased by -4.16%. In the past year, price decreased by -21.94%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Exscientia Plc engages in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of therapeutic compounds. The company is headquartered in Oxford, Oxfordshire and currently employs 483 full-time employees. The company went IPO on 2021-10-01. The firm combines precision design with integrated experimentation to invent and develop drugs. The company uses artificial intelligence (AI) in drug discovery to progress AI-designed small molecules into a clinical setting. The company uses the patient's tissue data to define optimal profiles for research, improve experimental assessment during design and improve outcomes in a medical setting. The company has developed an internal pipeline focused on oncology, while its partnered pipeline extends to various other therapeutic areas. The company combines genetic data and global literature in machine learning models to anticipate and confirm disease-target associations. The firm's experimental platform records responses in real patient samples allowing it to generate high-precision views of potential patient response. Its product pipeline consists of GTAEXS617, EXS4318, EXS74539, and EXS73565.
EXSCIENTIA PLC
The Schrodinger Building, Oxford Science Park
Oxford OXFORDSHIRE GB
Employees: 483
Company Website: https://www.exscientia.ai/
Phone: 441865818941
The current stock price of EXAI is 4.84 USD. The price increased by 3.2% in the last trading session.
The exchange symbol of EXSCIENTIA PLC is EXAI and it is listed on the Nasdaq exchange.
EXAI stock is listed on the Nasdaq exchange.
8 analysts have analysed EXAI and the average price target is 5.46 USD. This implies a price increase of 12.75% is expected in the next year compared to the current price of 4.84. Check the EXSCIENTIA PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
EXSCIENTIA PLC (EXAI) has a market capitalization of 633.18M USD. This makes EXAI a Small Cap stock.
EXSCIENTIA PLC (EXAI) currently has 483 employees.
EXSCIENTIA PLC (EXAI) has a support level at 4.64 and a resistance level at 5.45. Check the full technical report for a detailed analysis of EXAI support and resistance levels.
The Revenue of EXSCIENTIA PLC (EXAI) is expected to grow by 63.9% in the next year. Check the estimates tab for more information on the EXAI EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
EXAI does not pay a dividend.
EXSCIENTIA PLC (EXAI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.65).
ChartMill assigns a technical rating of 1 / 10 to EXAI. When comparing the yearly performance of all stocks, EXAI is a bad performer in the overall market: 87.66% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to EXAI. EXAI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months EXAI reported a non-GAAP Earnings per Share(EPS) of -1.65. The EPS increased by 5.11% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -25.37% | ||
ROE | -36.43% | ||
Debt/Equity | 0.05 |
ChartMill assigns a Buy % Consensus number of 48% to EXAI. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 42.38% and a revenue growth 63.9% for EXAI